Education
About Us
Working with TipRanks
Follow Us
BioLife Solutions Inc (BLFS)
:BLFS
Top Page
BioLife Solutions
(NASDAQ:BLFS)
55Neutral
Positive Factors
Financial Performance
BioLife Solutions reported strong financial performance in 4Q24, with total revenue exceeding projections and a net loss lower than expected.
Growth Potential
The company's focus on core business and cleaning up non-core assets is expected to enhance its business profile and drive profitability.
Negative Factors
Regulatory Concerns
Even if staffing and funding concerns at US regulatory agencies cast a pall over the prospects for approvals for new cell & gene therapies, BioLife’s cell processing products can still grow through the increased use of already existing CGT therapies and the expansion of clinical trial activity.
BioLife Solutions (BLFS) vs. S&P 500 (SPY)
Market Cap
$1.25B
Dividend YieldN/A
Average Volume (3M)332.60K
Price to Earnings (P/E)―
Beta (1Y)2.25
Revenue Growth-20.89%
EPS Growth83.44%
CountryUS
Employees414
SectorHealthcare
Sector Strength78
IndustryMedical Equipment & Supplies
Share Statistics
EPS (TTM)-0.26
Shares Outstanding47,000,000
10 Day Avg. Volume455,060
30 Day Avg. Volume332,595
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14.21
Price to Cash Flow (P/CF)177.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$31.33Price Target Upside17.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
BioLife Solutions Business Overview & Revenue Model
Company DescriptionBioLife Solutions, Inc. (BLFS) is a leading developer and supplier of bioproduction tools and services within the life sciences industry. The company specializes in providing biopreservation media, automated thawing devices, and related services that ensure the integrity and functionality of biologic materials. BioLife Solutions' core products are used in cellular therapy, gene therapy, and regenerative medicine applications, making it a critical player in advancing cutting-edge medical treatments.
How the Company Makes MoneyBioLife Solutions generates revenue through the sale of its proprietary biopreservation media and automated thawing systems. These products are essential for maintaining the viability and potency of sensitive biological materials during transport and storage. The company's revenue streams include direct sales to biotechnology and pharmaceutical companies, as well as academic and research institutions involved in cell and gene therapy development. Additionally, BioLife Solutions benefits from strategic partnerships and collaborations that enhance its market reach and technological capabilities, contributing to its financial performance.
BioLife Solutions Financial Statement Overview
Summary
BioLife Solutions faces challenges in profitability and revenue growth, with negative margins and decreased revenues impacting the income statement. The balance sheet shows a strong equity base but has been weakened by recent negative equity. Cash flow performance is mixed, highlighting the need for better cash management strategies. The company must focus on improving operational efficiency and profitability to enhance financial health.Income Statement
BioLife Solutions has experienced a significant decline in revenue and profit margins. The revenue growth rate shows a downward trend, and both EBIT and EBITDA margins are negative, indicating operational challenges. The company also struggles with negative net income, reflecting a need for operational improvements.40
Negative
Balance Sheet
The company has a strong equity base with a low debt-to-equity ratio, indicating minimal leverage risks. However, the negative stockholders' equity in recent years raises concerns about the company's financial stability. The equity ratio suggests a solid asset base, but the historical negative equity needs addressing.65
Positive
Cash Flow
Cash flow generation has been inconsistent, with occasional positive free cash flow but primarily negative trends. The operating cash flow to net income ratio indicates some cash generation ability despite net losses. Overall, cash flow management needs improvement to ensure sustainability.50
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 82.25M | 143.27M | 161.76M | 119.16M | 48.09M | Gross Profit |
| 57.75M | 46.75M | 53.82M | 37.75M | 27.44M | EBIT |
| -7.13M | -70.83M | -39.91M | -30.37M | -3.33M | EBITDA |
| 1.53M | -45.24M | -23.19M | -17.78M | 1.07M | Net Income Common Stockholders |
| -20.18M | -66.43M | -139.81M | -8.38M | 2.67M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 104.58M | 51.70M | 64.06M | 69.87M | 90.46M | Total Assets |
| 399.49M | 412.71M | 450.23M | 552.60M | 234.83M | Total Debt |
| 25.18M | 42.69M | 43.71M | 26.88M | 11.15M | Net Debt |
| -70.21M | 7.28M | 24.27M | -42.99M | -79.30M | Total Liabilities |
| 50.58M | 75.05M | 86.04M | 71.85M | 29.58M | Stockholders Equity |
| 348.91M | 337.66M | -246.91M | 480.75M | 205.25M |
| Cash Flow | Free Cash Flow | |||
| 5.20M | -18.88M | -18.87M | -13.22M | 1.88M | Operating Cash Flow |
| 8.43M | -12.50M | -8.49M | -4.84M | 6.51M | Investing Cash Flow |
| 58.30M | 17.84M | -58.12M | -12.64M | -23.73M | Financing Cash Flow |
| -6.78M | 10.59M | 16.32M | -2.78M | 101.22M |
BioLife Solutions Technical Analysis
Positive
26.62
Price Trends
26.60
Positive
25.80
Positive
24.39
Positive
Market Momentum
-0.29
Negative
52.83
Neutral
55.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLFS, the sentiment is Positive. The current price of 26.62 is above the 20-day moving average (MA) of 26.09, above the 50-day MA of 26.60, and above the 200-day MA of 24.39, indicating a bullish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 52.83 is Neutral, neither overbought nor oversold. The STOCH value of 55.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BLFS.
BioLife Solutions Risk Analysis
BioLife Solutions disclosed 31 risk factors in its most recent earnings report. BioLife Solutions reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioLife Solutions Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $991.04M | ― | -62.41% | ― | 5.10% | 30.45% | |
55 Neutral | $1.25B | ― | -6.14% | ― | -20.89% | 83.44% | |
53 Neutral | $3.19B | ― | -5.76% | ― | 5.28% | -292.14% | |
49 Neutral | $234.58M | ― | -25.76% | ― | -2.09% | -13.01% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% | |
46 Neutral | $149.97M | ― | -144.19% | ― | -14.79% | -1.57% | |
43 Neutral | $2.23B | ― | -46.67% | ― | 18.82% | 19.76% |
* Healthcare Sector Average
Performance Comparison
BLFS
BioLife Solutions
26.62
9.97
59.88%
ICUI
ICU Medical
138.99
38.15
37.83%
STXS
Stereotaxis
1.79
-0.69
-27.82%
CYRX
CryoPort
6.65
-9.65
-59.20%
NVCR
NovoCure
21.32
6.03
39.44%
ADPT
Adaptive Biotechnologies
7.49
3.90
108.64%
BioLife Solutions Earnings Call Summary
Earnings Call Date: Mar 3, 2025 | % Change Since: 10.92% | Next Earnings Date: May 8, 2025
Earnings Call Sentiment Positive
The earnings call for BioLife Solutions reflected a positive outlook with significant achievements in strategic portfolio reshaping, improved financial metrics, and a strong cash position. Despite some declines in specific platform revenues and ongoing operating losses, the company is well-positioned for growth in 2025 with record Cell Processing revenue and a strong growth outlook.Highlights
Strategic Portfolio Reshaping
BioLife Solutions strategically reshaped its portfolio in 2024, focusing on cell and gene therapies, divesting non-core product lines, and improving financial profiles.
Improved Financial Metrics
GAAP gross margin doubled from 31% in 2023 to 62% in 2024. Adjusted EBITDA was positive $16 million (19% of revenue), compared with negative $5 million in 2023.
Strong Cash Position
The company ended 2024 with $109 million in cash, up from $45 million in 2023, while paying down $5 million of principal on its bank debt.
Record Cell Processing Revenue
Cell Processing platform revenue was $20.3 million in Q4, up 7% over Q3 and a year-over-year increase of 37%. Full-year Cell Processing revenue totaled $74 million, increasing 12% compared to 2023.
2025 Growth Outlook
BioLife Solutions anticipates 2025 revenue growth of 16% to 20%, with Cell Processing revenue expected to grow between 18% to 21%.
Lowlights
Decline in Evo and Thaw Platform Revenue
Evo and Thaw platform revenue for Q4 2024 was $2.4 million, a decrease of $200,000 or 8% from the same period in 2023.
Ongoing Operating Losses
GAAP operating loss for Q4 2024 was $2.1 million, although this was an improvement from $7.6 million in the prior year.
Company Guidance
During the BioLife Solutions' Q4 2024 conference call, the company provided revenue guidance for 2025, projecting total revenues between $95.5 million and $99 million, representing a growth of 16% to 20% compared to 2024. The Cell Processing platform is expected to contribute significantly to this growth, with anticipated revenue of $86.5 million to $89 million, reflecting an 18% to 21% increase. The Evo and Thaw platform is expected to generate $9 million to $10 million, marking a 3% to 15% growth. The company also aims for adjusted gross margins in the mid-60s and anticipates expanding adjusted EBITDA margins in 2025. The positive outlook is driven by continued growth from their Cell Processing platform, focusing on deepening relationships with existing customers and exploring cross-sell opportunities to enhance revenue.BioLife Solutions Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
BioLife Solutions Strengthens Board with Tony J. Hunt Appointment
Positive
Dec 20, 2024
BioLife Solutions has appointed Tony J. Hunt, Executive Chairman of Repligen Corporation, to its board of directors effective January 2, 2025. Mr. Hunt, recognized for his leadership in bioprocessing innovation, is expected to enhance BioLife’s strategic focus on the CGT market with his extensive industry experience, contributing to the company’s growth and innovation efforts. This appointment reflects BioLife’s commitment to strengthening its position in the bioprocessing sector and supporting its mission of delivering top-tier bioproduction workflows.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.